I had a critical role in the development of the first commercial monoclonal antibody (Remicade) the first commercial gene therapy in the Western world (Glybera) and multiple gene therapies reaching the clinic clinic for acute intermittent porphyria, lysosomal storage diseases and neurodegenerative diseases. I led the development of Hemgenix (AAV5-FIX) for which the FDA accepted the Biologics License Application for priority review in May 2022, as well as the Huntington silencing program at uniQure. I was one of the founding partners, former Managing Partner and current Operating Partner at Forbion Capital Partners, a venture capital firm investing in the life sciences in Europe and North America. I have more than 20 years experience at boards of private, Euronext- and Nasdaq-listed companies, chairing audit, compensation, nomination and governance committees, and have served as CEO of a Euronext-listed company. I was trained as an internist and board-certified gastroenterologist, received a doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995. In 1998 I co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure; NASDAQ: QURE ), a gene therapy company that develops AAV-based gene therapy products. From 2001 until 2004, I chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. I have authored more than 80 book chapters, 600 peer review scientific papers, have organized several large international scientific conferences, and supervised more than 40 PhD students. Bibliographic summary (Google Scholar September 2024: Citations 73407; H-Index: 132).In 2020 I co-founded VectorY Therapeutics, a gene therapy company based in Amsterdam that develops novel AAV vectors delivering molecular binders (VecTabs) and protein degraders (VecTrons) that allow precision targeting of the protein misfolding and aggregation which is central to the pathogenesis of neurodegenerative diseases. VectorY reported preclinical therapeutic activity of VecTabs and VecTrons at several international scientific meetings.I like to cycle (road, gravel, MTB) and I am co-owner of two bicycle shops in the Netherlands.